Emergence of a BCR::ABL1 rearrangement following a uniquely complex clonal evolution pattern in a patient undergoing Fms-like tyrosine kinase 3 inhibitor therapy for acute myeloid leukemia

Int J Lab Hematol. 2023 Apr;45(2):e24-e27. doi: 10.1111/ijlh.13973. Epub 2022 Sep 30.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Clonal Evolution* / genetics
  • Drug Resistance, Neoplasm
  • Fusion Proteins, bcr-abl / genetics
  • Humans
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics
  • Protein Kinase Inhibitors / therapeutic use
  • fms-Like Tyrosine Kinase 3* / antagonists & inhibitors

Substances

  • Antineoplastic Agents
  • fms-Like Tyrosine Kinase 3
  • Fusion Proteins, bcr-abl
  • Protein Kinase Inhibitors
  • ABL1 protein, human
  • BCR protein, human